Research Funding Announcements | Lewy Body Dementia Association LBDA

Research Funding Announcements

Stay up-to-date on LBD-relevant funding opportunity announcements from LBDA and federal agencies like the National Institutes of Health and Department of Defense.

LBDA

None at this time. For future funding opportunities, please note LBDA's Policy on Indirect Rates.

NATIONAL INSTITUTES OF HEALTH

Title: Notice of Special Interest: Administrative Supplements for NIA-VA Mentored Physician-Scientist Award in Alzheimer’s Disease and its Related Dementias (AD/ADRD)
Notice Number:
 
NOT-AG-19-011
Issued by: National Institute on Aging (NIA)
Activity Code: VA IK2; NIA administrative supplement
Description The purpose of this initiative is to increase the number of early stage physician-scientists in Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD) research and improve patient care for veterans. To accomplish this goal, NIA and the U.S. Department of Veterans Affairs (VA) have created a two-part opportunity for early career VA physician-scientists to pair with both VA- and NIA-funded mentors in the AD/ADRD field . This will also facilitate the development of a sustainable process for collaboration and address key barriers or challenges that often hinder communication, sharing of resources, and increased coordination between the VA and NIA.
Open Date (Earliest Submission Date): October 1, 2019
Letters of Intent Due Date: March 9, 2020 for Spring Cycle
Application Due Date(s) Dates are aligned with the VA receipt dates for funding in FY 2020 – for Spring Cycle - May 6, 2020, by 5:00 PM local time of the applicant organization.
Funds Available and Anticipated Number of Awards Up to 10 awards
Award Budget: IK2 award - $65,000/year
NIA administrative supplement – up to $185,000 a year
Award Project Period: Up to 5 years
 
Scientific/Research Contacts Lisa A. Opanashuk, Ph.D. 
National Institute on Aging (NIA)
Telephone: 301-827-5422
Email: Lisa.Opanashuk@nih.gov
Title: Notice of Intent to Publish a Funding Opportunity Announcement for Impact of Alcohol on the Onset and Progression of Alzheimer’s Disease and Its Related Dementias (R01 - Clinical Trial Optional)
Notice Number:
 
OT-AA-19-026
Issued by: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute on Aging (NIA)
Activity Code: R01
Description National Institute on Alcohol Abuse and Alcoholism (NIAAA) in partnership with the National Institute on Aging (NIA) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to investigate mechanisms underlying the influence of alcohol on the onset and progression of Alzheimer’s disease and its related dementias.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects.

The FOA is expected to be published in Fall 2019 with an expected application due date in Spring 2020.

This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

Funds Available and Anticipated Number of Awards $3 million for 6-8 awards
Award Budget: $250,00 direct costs/year
Scientific/Research Contacts Changhai Cui, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
301-443-1678
Email: changhai.cui@nih.gov
 
Bradley C. Wise, Ph.D.
National Institute of Aging (NIA)
Telephone:301-496-9350
Email: WiseB@nia.nih.gov
Title: Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)
Notice Number:
 
PAR-19-374
Issued by: National Institute on Aging (NIA)
Activity Code: U19
Description This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions. Resources and study expertise will be tightly coordinated across multiple sites or cores, such as:

  • One or more coordinating centers
  • Clinical or study sites
  • Specialized cores, such as for data management and analysis, measurement and phenotyping, animal models, etc.

Examples of the kinds of studies supported under this announcement include, but are not limited to, one or a combination of the following:
 
Large-scale longitudinal observational studies of diseases or conditions that are common in aging populations involving integration of multiple clinical outcomes with molecular, genetic, or other mechanistic data.

  • Large-scale, multi-site intervention studies in human subjects and/or animal models for aging-related conditions involving multiple endpoints to assess efficacy or effectiveness and to elucidate mechanisms.
  • Translation of basic science findings into pre-clinical or clinical studies, or of clinical findings into practice or community settings, for prevention, diagnosis, or treatment of aging-related conditions, requiring coordination of broad multidisciplinary expertise across multiple settings.

The structure and approach of proposed projects will vary depending on the hypotheses under study; however, it is expected that all projects will focus on an overarching scientific question that integrates all study components into a unified whole.

Open Date (Earliest Submission Date): September 28, 2019
Letters of Intent Due Date: 30 days prior to the application due date
Application Due Date(s) The first submission date for this FOA is October 28, 2019. After this off-cycle application due date, future application due dates will follow the standard due dates, with the next submission date of January 25, 2020.
Funds Available and Anticipated Number of Awards The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Award Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Award Project Period: The maximum project period is 5 years.  
Scientific/Research Contacts Sanoj Suneja, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-402-7710
Email: sunejas@mail.nih.gov
Title: Notice of Intent to Publish a Funding Opportunity Announcement for Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial not allowed)
Notice Number:
 
NOT-MH-19-043
Issued by: National Institute of Mental Health (NIMH)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Activity Code: R01
Description The NIMH and NIAAA intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research on the development of PET and SPECT tracers for molecular targets (e.g., receptors, intracellular messengers, disease-related proteins) that are implicated in mental disorders and alcohol abuse as tools to study disease pathophysiology and/or for assessing target engagement of potential therapeutic candidates. The objective of this FOA is to stimulate research in the identification and development of PET and SPECT probes for disorders of primary interest to the NIMH or NIAAA.
 
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
 
The FOA is expected to be published in January 8, 2020 with an expected application due date in February 5, 2020 .
Open Date (Earliest Submission Date): The FOA is expected to be published in January 8, 2020
Application Due Date(s) The expected application due date will be February 5, 2020 .
Scientific/Research Contacts Enrique Michelotti, PhD
NIMH
301- 443- 5415
michelottiel@mail.nih.gov
Title: Low Cost Detection of Cognitive Decline in Clinical Settings (R61/R33 Clinical Trial Required)
Notice Number:
 
RFA-AG-20-050
Issued by: National Institute on Aging (NIA)
Activity Code: R61/R33 Exploratory/Developmental  Phased Award
Description This Funding Opportunity Announcement (FOA) invites applications to pursue development and validation studies of cognitive screening instruments or assessments in clinical settings and to translate these screening and assessment tools into electronic health record (EHR) systems that can assist physicians in making clinically meaningful care recommendations for patients experiencing cognitive decline.
 
This FOA will support an R61 pilot phase (Stage I) which will allow researchers to develop and validate tools for cognitive assessment and then create scalable, tailored interventions for patients experiencing cognitive decline to help overcome barriers to uptake. If successful, researchers may transition to an R33 phase (Stage IV) for implementation of pragmatic trials. All applicants are required to address health disparities. This FOA does not require preliminary data.
 
The transition from the R61 to the R33 phase of the award will be administratively reviewed for successful completion of the go/no-go criteria specified for the R61 phase.
Open Date (Earliest Submission Date): December 30, 2019
Letters of Intent Due Date: December 30, 2019
Application Due Date(s) January 30, 2020
Funds Available and Anticipated Number of Awards NIA intends to commit $4M in FY 2020 to fund 3-4 awards.
Award Budget: For the R61 planning phase, the combined budget for direct costs may not exceed $750,000, with no more than $500,000 requested in any single year.
For the R33 implementation phase, the combined budget for direct costs may not exceed $3M. 
 
Applicant's budgets need to reflect the actual needs of the proposed project.
Award Project Period: The maximum project period for the R61 planning phase is 2 years.
 
The maximum project period for the R33 phase is 3 years.
Scientific/Research Contacts Partha Bhattacharyya, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: bhattacharyyap@mail.nih.gov
Title: Low Cost Detection of Cognitive Decline in Clinical Settings (R01 Clinical Trial Required)
Notice Number:
 
RFA-AG-20-051
Issued by: National Institute on Aging (NIA)
Activity Code: R01
Description This Funding Opportunity Announcement (FOA) invites applications to pursue validation studies of cognitive screening instruments or assessments in clinical settings and to translate these screening and assessment tools into electronic health record (EHR) systems that can assist physicians in making clinically meaningful care recommendations for patients experiencing cognitive decline. This FOA requires prior preliminary data gathered during the development of cognitive screening tools and/or assessments. This FOA will also support research to validate these tools as well as their implementation in large clinical settings. Plans for validation of cognitive impairment against relevant Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) biomarkers are encouraged but not required.
Open Date (Earliest Submission Date): December 30, 2019
Letters of Intent Due Date: December 30, 2019
Application Due Date(s) January 30,2020
Funds Available and Anticipated Number of Awards  
NIA intends to commit $4 million in FY 2020 to fund 2-3 awards.
Award Budget: Applicant's budgets may not exceed $2 million per year in direct costs and may not exceed $4.25 million in total direct costs across five years.     Applicant's budgets need to reflect the actual needs of the proposed project.
Award Project Period: The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Scientific/Research Contacts Partha Bhattacharyya, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: bhattacharyyap@mail.nih.gov
Title: Social Epigenomics Research Focused on Minority Health and Health Disparities (R01-Clinical Trial Not Allowed)
Notice Number:
 
PAR-19-372
Issued by: National Institute on Minority Health and Health Disparities (NIMHD)
National Institute on Aging (NIA)
National Human Genome Research Institute (NHGRI)
Activity Code: R01
Description The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate human epigenomic investigations focused on identifying and characterizing the mechanisms by which social experiences at various stages in life, both positive and negative, affect gene function and thereby influence health trajectories or modify disease risk in racial/ethnic minority and other health disparity populations.
Open Date (Earliest Submission Date): October 06, 2019
Application Due Date(s) November 6, 2019, November 6, 2020, November 8, 2021
Funds Available and Anticipated Number of Awards The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Award Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Award Project Period: The scope of the proposed project should determine the project period. The maximum project period is 5 years
Scientific/Research Contacts Rina Das, PhD
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-496-3996
Email: dasr2@mail.nih.gov
 
Lucia Hindorff, Ph.D.
National Human Genome Research Institute
Phone: 240-271-1509
Email: hindorffl@mail.nih.gov
 
Amelia Karraker, PhD
National Institute on Aging (NIA)
Telephone: 301-496-3138
Email: Amelia.Karraker@nih.gov
Title: MD-PhD Training Program in Alzheimer's Disease and Its Related Dementias and the Behavioral and Social Sciences (T32)
Notice Number:
 
RFA-AG-20-032
Issued by: National Institute on Aging (NIA)
Activity Code: T32
Description NIA's MD-PhD Training Program in Alzheimer's Disease and Its Related Dementias and the Behavioral and Social Sciences is designed to help strengthen the pipeline of physician-scientist leaders dedicated to using social and behavioral science approaches to addressing the nation's challenges posed by Alzheimer's disease and its related dementias (AD/ADRD). This FOA provides support to eligible domestic institutions to develop and implement effective approaches to integrated dual-degree training leading to the award of both an MD and a research doctorate degree (PhD or equivalent). This FOA invites applications from institutions with externally funded grants in the social/behavioral sciences that are relevant to the research topics proposed under this FOA. Fields of graduate training that are responsive to this FOA are economics, health economics, health services research, public policy, healthcare policy, social work, demography, sociology, social epidemiology, and psychology. Integrated medical and graduate research training programs may be built around single disciplines or may be multidisciplinary, may be flexible in structure, and should be consistent with individual institutional strengths. Proposed training programs should be flexible and adaptable in providing each trainee with the appropriate background in the social/behavioral sciences relevant to AD/ADRD research and clinical practice, yet be rigorous enough to enable graduates to function independently in both basic social/behavioral science research and clinical investigation. 
 
This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.
Open Date (Earliest Submission Date): September 28, 2019
Letters of Intent Due Date: September 28, 2019
Application Due Date(s) October 28, 2019
Funds Available and Anticipated Number of Awards NIA intends to commit $777,000 in direct costs in FY 2020 to fund four awards
Award Budget: Each institutional training program may appoint up to four trainees annually. Budgets need to reflect the actual needs of the proposed project.
Award Project Period:  
Awards will be made for five years.
Scientific/Research Contacts Georgeanne E. Patmios
National Institute on Aging (NIA)
Telephone: 301-496-3136
Email: PatmiosG@mail.nih.gov
Title: Peripheral Pathology in the Lewy Body Dementias (R01 Clinical Trial Not Allowed)
Notice Number:
 
RFA-NS-20-014
Issued by: National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
Activity Code R01
Description The purpose of this initiative is to identify potential diagnostic markers for the Lewy body dementias using non-blood or non-CSF peripheral specimens and tissues (e.g., skin, salivary gland, gastrointestinal tract, etc.). Blood and CSF have traditionally and extensively been examined for neurodegenerative disease biomarkers; however, research suggests that abnormal alpha-synuclein accumulation occurs in other peripheral tissues and specimens early in the disease course and may provide opportunities for early diagnosis and future treatment development.
Open Date (Earliest Submission Date): November 02, 2019
LOI Date: n/a
Application Due Date(s) December 3, 2019 by 5:00 PM local time of applicant organization.
Funds Available and Anticipated Number of Awards NINDS intends to commit $3,750,000 in FY 2020 to fund 5 awards.
Award Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Scientific/Research Contacts Debra Babcock, PhD, MD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9964
Email: dbabcock@mail.nih.gov
 
Lisa Opanashuk, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-827-5422
Email: lisa.opanashuk@nih.gov
Title: Mechanistic Basis of TDP-43-dependent Pathobiology in Common Dementias (R01 Clinical Trial not Allowed)
Notice Number:
 
RFA-NS-20-005
Issued by: National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
Activity Code R01
Description The purpose of this funding opportunity announcement (FOA) is to support hypothesis-testing research on the systems, cellular and/or molecular mechanisms and consequences of TDP-43 proteinopathy in common dementias using whole animal models, animal/human cellular model systems, as well as postmortem tissue and other biospecimens. Research on TDP-43 proteinopathy in common dementias, including the clinical syndrome of Alzheimer's disease (AD), multiple etiology dementias (MED) and related dementia syndromes is the focus of this FOA. In addition, comparative studies of TDP-43 proteinopathy in common and rare neurodegenerative diseases, as well as during normal aging and in pre-symptomatic disease stages are within scope.
Open Date (Earliest Submission Date): October 15, 2019
LOI Date: October 15, 2019
Application Due Date(s) November 15, 2019 by 5:00 PM local time of applicant organization.
Funds Available and Anticipated Number of Awards NINDS intends to commit $6,750,000 in FY 2020 to fund 8-10 awards.
Award Budget: Application budgets are limited to up to $500,000 direct costs per year, and should reflect the actual needs of the proposed project
Scientific/Research Contacts Amelie K. Gubitz, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-5680
Email: gubitza@ninds.nih.gov
Title: Pilot pragmatic clinical trials for people living with Alzheimer's disease and Alzheimer’s disease-related dementias (AD/ADRD) and their caregivers
Notice Number:
 
RFA-IMPACT-19-P01
Issued by: National Institute on Aging (NIA) Impact Collaboratory
Description The National Institute on Aging (NIA) Imbedded Pragmatic AD/ADRD Clinical
Trials (IMPACT) Collaboratory (U54AG063546) was established in 2019 to
build the nation’s capacity to conduct embedded pragmatic clinical trials
(ePCTs) of non-pharmacologic interventions within health care systems to
improve the care of people living with AD/ADRD and their caregivers.
 
The IMPACT Collaboratory funds several one-year pilot studies annually. Pilot
studies are meant to generate the preliminary data necessary to design and
conduct a future full-scale ePCT for which funding would be sought from the
National Institutes of Health (R01 or equivalent) or other sources. The
IMPACT Collaboratory prioritizes applications that address dementia care for
people of all backgrounds.
 
Pilot studies must:

  • Pilot test a non-pharmacological intervention targeting people living with AD/ADRD and/or their caregivers using a pragmatic trial design.
  • Implement the intervention in two or more health care systems or sites within health care systems (e.g., ≥ 2 nursing homes, hospitals, healthcare provider practices).
  • Be feasible within the one-year time frame
LOI Date: Rolling through October 11, 2019 @5pm ET
Application Due Date(s) December 6, 2019 @ 5pm EST
Funds Available and Anticipated Number of Awards IMPACT Collaboratory will fund 3-4 one-year, non-renewable pilot studies
Award Budget: Awards are for one year, up to $150,000 (total costs) and are non-renewable.
No-cost extensions will be permitted with strong rationale. Only a single
Principal Investigator (PI) is allowed, and only one application per individual PI
is permitted per funding cycle.
Scientific/Research Contacts Ab Brody, PhD, RN, FAAN
Pilot Core Leader
IMPACT Collaboratory
Email: IMPACTcollaboratory@hsl.harvard.edu
Title: Solicitation of Nominations for the 2020 National Institute of Neurological Disorders and Stroke (NINDS) Landis Award for Outstanding Mentorship
Notice Number: NOT-NS-19-080
Issued by: National Institute of Neurological Disorders and Stroke (NINDS)
Description: This award provides $100,000.00 (direct costs) to up to five (5) faculty members who are considered to be outstanding mentors and trainers to help foster the research career development of additional students and post-doctorates.  NINDS invites nominations of outstanding mentors who are 21 years or more from the start of their first tenure-track or equivalent faculty position (i.e., the start date of their first tenure-track or equivalent faculty position was in calendar year 1998 or earlier). Selection for this award is based on nomination from those who have first-hand knowledge of an individual's outstanding mentorship.
Application Due Date(s): Complete a nomination form by December 1, 2019
Funds Available and Anticipated Number of Awards: $100,000.00 (direct costs) to up to five (5) faculty members
Scientific/Research Contacts: Stephen Korn
Title: Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)
Notice Number: PAR-19-302
Issued by: National Institute on Aging
Description This FOA provides a vehicle for submitting investigator-initiated grant applications to conduct multi-site clinical trials of all phases and stages on topics relevant to NIA's mission.
Open Date (Earliest Submission Date): September 05, 2019
Application Due Date(s): The first standard application due date for this FOA is October 5, 2019.
Expiration Date: September 08, 2022
Funds Available and Anticipated Number of Awards: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Award Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Award Project Period: The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Scientific/Research Contacts: Sergei Romashkan, M.D., Ph.D., Lisa Onken, Ph.D., Laurie Ryan, Ph.D.
Title: Transition to Aging Research Award for Predoctoral Students (F99/K00)
Notice Number: RFA-AG-20-009
Issued by: National Institute on Aging
Description: NIA invites outstanding graduate students from a wide range of broad research areas including, but not limited to, statistics, neuroscience, physics, immunology, microbiology, informatics, data sciences, and engineering who are interested in receiving aging-related postdoctoral training to apply for this award.
Open Date (Earliest Submission Date): September 22, 2019
Application Due Date(s): October 22, 2019
Scientific Merit Review: February/March 2020
Funds Available and Anticipated Number of Awards: NIA intends to commit $450,000 in FY 2020 to fund 7-10 awards.
Scientific/Research Contacts: Sergei Romashkan, M.D., Ph.D.
Title: Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
Notice Number: PAR-19-315
Issued by: National Institute of Neurological Disorders and Stroke
National Institute on Aging
Description: The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.
Open Date (Earliest Submission Date): August 9, 2019
LOI Date: 30 days prior to due date
Application Receipt Date(s): September 4, 2019; February 14, 2020; July 20, 2020; February 17, 2021; July 19, 2021; and February 14, 2022
Funds Available and Anticipated Number of Awards: Contingent upon NIH appropriations and the submission of meritorious applications.
Scientific/Research Contacts: Mary Ann Pelleymounter, PhD (NINDS), Julia Bachman, PhD,  (NINDS) Suzana Petanceska, Ph.D. (NIA)

 
 
 

*LBDA Policy on Indirect Rates
Grant proposals to LBDA should not exceed a 10% indirect rate; this is the maximum allowed for the primary applicant organization and any sub-grantees or contractors. (If a grantee has an indirect cost rate lower than 10%, they should not increase the funding to the maximum allowed.) LBDA reserves the right to allow for a higher indirect rate in rare situations as warranted. Written permission from LBDA’s contact person for the grant opportunity is required in advance of submitting a proposal with an indirect rate higher than 10%.